LBA is an alternative investment firm that invests in high growth private companies across the technology sector.

As forward thinking investors, through our private investment groups and funds, we aim to generate attractive investment returns by finding and backing the best management teams with scalable, proven propositions and providing them with the capital and expertise that they need.

About LBA

LBA was founded in 1982 as Lenta Ventures with a remit to connect high growth early stage companies with a network of experienced business angels.

Since 2009, LBA has been a wholly owned subsidiary of Angel Capital Group with its core LBA private investment group having expanded significantly from circa 70 members to over 220 at present.

LBA launched its first LBA EIS roundtable syndicate fund in January 2010. These funds have now invested in over 40 portfolio companies.

Alongside its core LBA private investor group, LBA has devised and delivered bespoke investor programmes focused on:

  • Digital tech in London (Angels in the City in collaboration with the City of London Corporation).
  • Medtech & life sciences (Angels in Medcity in collaboration with Medcity)
  • Downstream and upstream space technologies (UK Space Tech Angels supported by Airbus venture in conjunction with Seraphim Capital).

Since 2009, LBA private investors and LBA EIS funds have invested in over 100 companies, investing as part of rounds totally over £100m. Significant co-investment has come through LBA’s co-investment partners, the £100m Angel Co-Fund and the £25m London Co-Investment Fund.

The team

A high calibre team, with years of combined investment experience. Ensuring your investment is in the best hands.
Alexander Sleigh
Investment Director
Callum Lee
Investment Manager
Yann Moulary
Investment Associate

Strategic Partners

We partner with established service providers who can add substantial value to our private investors and investee companies.



London Business Angels news

Read about our latest investments and news from the London Business Angels team.
LBA syndicate supports Eagle Genomic’s £1m investment round
LBA syndicate supports Eagle Genomic’s £1m investment round

Eagle Genomics, a Cambridge based bioinformatics specialist, has closed a...

Read More
Videregen’s lead product granted EU orphan drug status
Videregen’s lead product granted EU orphan drug status

Recognition of potential of personalised trachea replacement in airways...

Read More

Contact us

Are you a company looking for investment? Or want to find out how to become an LBA investor? Use the form below to get in touch.